3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Head & Neck
2
Gastrointestinal
2
Thoracic
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
86
Lung Neoplasms
32
Small Cell Lung Carcinoma
18
Melanoma
17
Mesothelioma
13
Neoplasms
11
Colorectal Neoplasms
9
Carcinoma, Renal Cell
9
Squamous Cell Carcinoma of Head and Neck
7
Neoplasm Metastasis
7
Mesothelioma, Malignant
7
Carcinoma, Transitional Cell
7
Ovarian Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Liver Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Kidney Neoplasms
4
Brain Neoplasms
4
Carcinoma, Merkel Cell
3
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Interventions
pembrolizumab
4
Trastuzumab
2
Interleukin-12 Subunit p35
2
Drug Therapy
2
tipifarnib
1
spartalizumab
1
seribantumab
1
pertuzumab
1
motexafin lutetium
1
entinostat
1
Thalidomide
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Observation
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Itraconazole
1
Irinotecan
1
Ipilimumab
1
Interleukin-12
1
Injections, Subcutaneous
1
Immunotherapy
1
Gemcitabine
1
Fluorouracil
1
Fentanyl
1
Escitalopram
1
Erlotinib Hydrochloride
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Ipilimumab
×
Thoracic
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts